Vical herpes

Dec 20, 2013 Sponsor: Vical. Information provided by (Responsible Party): Vical MedlinePlus related topics: Genital Herpes Herpes Simplex An experimental HSV vaccine was not effective in preventing genital HSV-2 Vical Incorporated is a biopharmaceutical research company based in San Diego ,

Dec 19, 2014 Some advancement on the herpes vaccine front: San Diego biotech Vical recently kicked off a Phase 12 trial of its Vaxfectin genital herpes

Oct 8, 2014 Vical has additional issued patents covering the composition and use of its Vaxfectin adjuvant. The six recently issued HSV-2 U.S. patents are HSV-2 is a herpes virus that is the leading cause of genital herpes worldwide for HSV-2 or genital herpes Vical is developing a therapeutic HSV-2 vaccine Oct 3, 2014 After decades of stagnancy in the herpes therapeutics space, a real San Diego39s Vical are speeding ahead in developing a herpes vaccine

Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in

Vical HSV Clinical Trial. Healthy HSV-2 Positive Men and Women Needed for Herpes Study. People for Flyer Healthy men and women aged 19-50 who have Dec 17, 2013 The initiation of this trial represents another milestone for Vical Our trial is designed to demonstrate reductions in the rate of HSV-2 that is

Sep 12, 2013 Vical39s HSV-2 DNA vaccine program, as seen below, involves collaboration with Lawrence Corey39s group at the Fred Hutchinson Research Feb 5, 2013 Vical Incorporated announces results of herpes vaccine trial testing its Vaxfectin-formulated plasmid DNA herpes vaccine on guinea pigs